HIV-associated thrombocytopenia is a dis- ease which can be recurrent to standard therapy which includes highly active antiretroviral therapy (HAART) therapy, steroids and immunoglobulin. We report a patient with HIV and hepatitis C who presented with resistant thrombocytopenia. Treatment with Eltrombopag – a thrombopoeitin receptor agonist showed initial good response with recurrence of thrombocytopenia. This novel agent could be considered as a treatment option prior to splenectomy and may be useful as a tempo- rizing measure.

+More

tempo rizing measure thrombopoeitin receptor agonist dis

Rajakrishnan Vijayakrishnan,Sourbha Dani,Aparna Ramasubramanian,Rekha Nair,Tony M. Samaha,.Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag. 1 (1),.

Rajakrishnan Vijayakrishnan,Sourbha Dani,Aparna Ramasubramanian,Rekha Nair,Tony M. Samaha,"Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag" 1

Rajakrishnan Vijayakrishnan,Sourbha Dani,Aparna Ramasubramanian,Rekha Nair,Tony M. Samaha,"Resistant thrombocytopenia in an HIV and hepatitis C patient: treatment response with novel agent eltrombopag"